NASDAQ:ZFGN - Zafgen Stock Price, Forecast & News

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

Zafgen Inc (NASDAQ:ZFGN) released its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.27) by $0.03. View Zafgen's Earnings History.

Zafgen is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Zafgen.

5 brokers have issued 1-year price objectives for Zafgen's stock. Their forecasts range from $0.78 to $17.00. On average, they anticipate Zafgen's share price to reach $7.70 in the next twelve months. This suggests a possible upside of 505.9% from the stock's current price. View Analyst Price Targets for Zafgen.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Zafgen.

Media headlines about ZFGN stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zafgen earned a news sentiment score of 0.7 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Zafgen.

Zafgen saw a increase in short interest in January. As of January 31st, there was short interest totalling 823,200 shares, an increase of 58.1% from the January 15th total of 520,800 shares. Based on an average trading volume of 673,400 shares, the short-interest ratio is currently 1.2 days. Currently, 2.5% of the shares of the company are sold short. View Zafgen's Current Options Chain.

Some companies that are related to Zafgen include Spero Therapeutics (SPRO), Kezar Life Sciences (KZR), GlycoMimetics (GLYC), Akorn (AKRX), Ovid Therapeutics (OVID), Neptune Wellness Solutions (NEPT), Scpharmaceuticals (SCPH), Tyme Technologies (TYME), Selecta Biosciences (SELB), Northwest Biotherapeutics (NWBO), Aptinyx (APTX), ContraFect (CFRX), Harrow Health (HROW), Avenue Therapeutics (ATXI) and NuCana (NCNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include CA (CA), Endologix (ELGX), Energy Transfer LP Unit (ET), SCYNEXIS (SCYX), TG Therapeutics (TGTX), BlackRock (BLK), Fate Therapeutics (FATE), Gilead Sciences (GILD), Micron Technology (MU) and AT&T (T).

Zafgen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (6.38%), Russell Investments Group Ltd. (1.06%), Point72 Asset Management L.P. (0.55%), Virtu Financial LLC (0.28%), Wedbush Securities Inc. (0.23%) and Jane Street Group LLC (0.16%). View Institutional Ownership Trends for Zafgen.

ZFGN stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Wedbush Securities Inc. and State Street Corp. View Insider Buying and Selling for Zafgen.

ZFGN stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Renaissance Technologies LLC, Russell Investments Group Ltd., Virtu Financial LLC and Jane Street Group LLC. View Insider Buying and Selling for Zafgen.

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZFGN stock can currently be purchased for approximately $1.27.

Zafgen has a market capitalization of $47.46 million. The biopharmaceutical company earns $-61,370,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Zafgen employs 38 workers across the globe.View Additional Information About Zafgen.

The official website for Zafgen is http://www.zafgen.com/.

Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]